BeiGene Ltd.
- Country
- π¨π³China
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
- Conditions
- Hormone-receptor-positive Breast CancerHER2-negative Breast CancerMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2025-01-03
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 92
- Registration Number
- NCT06756932
- Locations
- πΊπΈ
Hoag Memorial Presbyterian, Newport Beach, California, United States
πΊπΈUniversity of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
πΊπΈMd Anderson Cancer Center, Houston, Texas, United States
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma
- Conditions
- Mantle Cell LymphomaB Cell Lymphoma
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 300
- Registration Number
- NCT06742996
- Locations
- πΊπΈ
University of Alabama At Birmingham Hospital, Birmingham, Alabama, United States
πΊπΈUniversity of Alabama At Birmingham Hospital, Birmingham, Alabama, United States
πΊπΈMayo Clinic Phoenix, Phoenix, Arizona, United States
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Conditions
- Chronic Lymphocytic LeukemiaCLL
- Interventions
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 56
- Registration Number
- NCT06697184
- Locations
- πΊπΈ
Moffitt Cancer Center, Tampa, Florida, United States
πΊπΈFort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
πΊπΈThe University of Kansas Cancer Center, Westwood, Kansas, United States
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung CancerLung CancerNSCLCNSCLC (Non-small Cell Lung Carcinoma)EGFR Activating MutationEGFR Mutation-Related Tumors
- Interventions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 93
- Registration Number
- NCT06685718
- Locations
- πΊπΈ
University of Colorado, Denver, Colorado, United States
πΊπΈUniversity of Colorado, Denver, Colorado, United States
πΊπΈUniversity of Miami, Miami, Florida, United States
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 87
- Registration Number
- NCT06637501
- Locations
- πΊπΈ
University of Miami, Miami, Florida, United States
πΊπΈCleveland Clinic Florida, Weston, Florida, United States
πΊπΈNorthwest Georgia Oncology Centers Marietta, Marietta, Georgia, United States
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- Conditions
- B-cell MalignancyRelapsed CancerRefractory CancerB-cell Lymphoma
- Interventions
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 80
- Registration Number
- NCT06634589
- Locations
- π§π·
Hospital Sirio Libanes Brasilia, Brasilia, Brazil
π§π·Ensino E Terapia de Inovacao Clinica Amo Etica, Salvador, Brazil
π§π·Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto, Sao Jose Do Rio Preto, Brazil
A First-in-Human Study of BG-C137, an Anti-FGFR2b Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 68
- Registration Number
- NCT06625593
- Locations
- πΊπΈ
Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California, United States
πΊπΈYale Cancer Center, New Haven, Connecticut, United States
πΊπΈMayo Clinic Rochester, Rochester, Minnesota, United States
A Study of BG-C477 in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 21
- Registration Number
- NCT06596473
- Locations
- πΊπΈ
City of Hope National Medical Center, Duarte, California, United States
πΊπΈYale University, Yale Cancer Center, New Haven, Connecticut, United States
πΊπΈThe University of Kansas Cancer Center, Westwood, Kansas, United States
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 87
- Registration Number
- NCT06598800
- Locations
- πΊπΈ
Hackensack University Medical Center, Hackensack, New Jersey, United States
πΊπΈThe University of Texas Md Anderson Cancer Center, Houston, Texas, United States
πΊπΈNext Virginia, Fairfax, Virginia, United States
An Investigational Study of BGB-58067 in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 92
- Registration Number
- NCT06589596
- Locations
- πΊπΈ
Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California, United States
πΊπΈAdventhealth, Celebration, Florida, United States
πΊπΈDana Farber Cancer Institute, Boston, Massachusetts, United States